FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.
Pharma & Biotech
Medical Devices & Diagnostics
Why Wenda Pharma’s Phase II data puts BET inhibition back in focus for NUT carcinoma
NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.
Pharma & Biotech
What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.